Hospital
BMH INC
BMH INC was paid $3.52M by Medicaid between Jan 2018 and Dec 2024, across 213 billing codes. Its largest line is 97530, Therapeutic activities, direct patient contact, each 15 minutes — 13% of everything it billed.
33Billing provider infoBMH INC
BLACKFOOT, ID 83221
BLACKFOOT, ID 83221
33aNPI1982805271assigned 05/31/2007
33bProvider typeCritical Access Hospital
28Total paid$3.52M
24GClaims218,932
24DCodes billed213
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Idaho
Rank by total paid#1 of 20
Median peer was paid$348K
This provider vs. median10×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ERICKSON, JACOB controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 66,610 | $1.22M | |
| 2019 | 65,304 | $1.20M | |
| 2020 | 44,062 | $882K | |
| 2021 | 10,310 | $46K | |
| 2022 | 13,498 | $78K | |
| 2023 | 15,009 | $80K | |
| 2024incomplete | 4,139 | $10K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 13% | 7,441 | 1,328 | $443K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 5.0% | 3,009 | 884 | $177K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.7% | 4,826 | 950 | $167K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.7% | 1,788 | 1,234 | $129K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.7% | 395 | 376 | $129K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.2% | 1,559 | 551 | $113K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3.1% | 2,267 | 1,671 | $108K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.9% | 287 | 240 | $101K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.7% | 2,620 | 1,805 | $96K |
| 80081 | 2.6% | 1,206 | 1,175 | $90K | |
| 80053 | Comprehensive metabolic panel | 2.5% | 13,014 | 11,036 | $88K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.5% | 4,305 | 3,231 | $88K |
201 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.5% | 15,969 | $87K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.3% | 6,536 | $82K |
| 99153 | Mod sedat endo service >5yrs | 2.1% | 1,099 | $74K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.0% | 2,014 | $70K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 408 | $69K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.0% | 2,013 | $69K |
| 87653 | 1.3% | 1,245 | $46K | |
| 99152 | 1.3% | 1,410 | $46K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.2% | 2,152 | $41K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.2% | 245 | $41K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 139 | $41K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 16,108 | $40K |
| 87507 | 1.0% | 102 | $37K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 800 | $34K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,168 | $30K |
| 87088 | <1% | 4,670 | $28K | |
| 82947 | <1% | 8,120 | $27K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 378 | $26K |
| 88342 | <1% | 360 | $23K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,640 | $23K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,180 | $23K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,095 | $23K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,506 | $21K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,819 | $20K |
| 99283 | Emergency room visit (moderate) | <1% | 691 | $20K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,097 | $20K |
| 80061 | Lipid panel | <1% | 2,563 | $19K |
| 97161 | <1% | 386 | $19K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 555 | $18K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 154 | $18K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,222 | $17K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 499 | $17K |
| 86141 | <1% | 2,641 | $17K | |
| 84439 | <1% | 2,749 | $16K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,705 | $16K |
| 88313 | <1% | 185 | $15K | |
| 80306 | <1% | 1,316 | $15K | |
| 81001 | <1% | 6,038 | $15K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 263 | $15K |
| 83880 | <1% | 1,011 | $15K | |
| 84702 | <1% | 845 | $13K | |
| 87660 | <1% | 582 | $13K | |
| 84484 | <1% | 2,406 | $12K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,488 | $12K |
| 87186 | <1% | 1,884 | $12K | |
| 81025 | <1% | 1,475 | $12K | |
| 87486 | <1% | 395 | $11K | |
| 87581 | <1% | 395 | $11K | |
| 87510 | <1% | 582 | $11K | |
| 87480 | <1% | 582 | $11K | |
| 87631 | <1% | 87 | $11K | |
| 82607 | <1% | 1,038 | $11K | |
| 97116 | <1% | 559 | $10K | |
| 82553 | <1% | 1,858 | $10K | |
| 90870 | <1% | 40 | $10K | |
| 87077 | <1% | 1,776 | $9K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,074 | $9K |
| 73030 | <1% | 666 | $9K | |
| 82728 | <1% | 905 | $9K | |
| 83690 | <1% | 1,507 | $9K | |
| 87641 | <1% | 359 | $8K | |
| 83605 | <1% | 1,624 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 608 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,317 | $8K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 558 | $8K |
| 72100 | <1% | 537 | $8K | |
| 85730 | <1% | 1,977 | $8K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 109 | $8K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 43 | $8K |
| 82550 | <1% | 2,147 | $7K | |
| 85610 | <1% | 2,519 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,921 | $7K |
| 88304 | <1% | 210 | $7K | |
| 83735 | <1% | 2,167 | $7K | |
| 84481 | <1% | 538 | $7K | |
| 73562 | <1% | 329 | $6K | |
| 84145 | <1% | 519 | $6K | |
| 82950 | <1% | 1,244 | $6K | |
| 97014 | <1% | 450 | $6K | |
| 73630 | <1% | 412 | $5K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 417 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,514 | $5K |
| 97016 | <1% | 328 | $4K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 833 | $4K |
| 82746 | <1% | 381 | $4K | |
| A4218 | Sterile saline or water, metered dose dispenser, 10 ml | <1% | 3,847 | $4K |
| 83525 | <1% | 518 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 132 | $4K |
| 83540 | <1% | 766 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 431 | $4K |
| 85380 | <1% | 483 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 671 | $3K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 270 | $3K |
| 88142 | <1% | 156 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 261 | $3K |
| 83970 | <1% | 134 | $3K | |
| 85652 | <1% | 1,186 | $3K | |
| 84403 | <1% | 130 | $3K | |
| 73610 | <1% | 196 | $3K | |
| 83550 | <1% | 388 | $3K | |
| 87640 | <1% | 357 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 210 | $2K |
| 87070 | <1% | 404 | $2K | |
| 73130 | <1% | 144 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 27 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 168 | $2K |
| 82570 | <1% | 477 | $2K | |
| 84270 | <1% | 93 | $2K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 348 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 70 | $2K |
| 84550 | <1% | 531 | $2K | |
| 74178 | <1% | 12 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 649 | $2K |
| 86038 | <1% | 137 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 29 | $1K |
| 83516 | <1% | 147 | $1K | |
| 73560 | <1% | 91 | $1K | |
| 86769 | <1% | 44 | $1K | |
| 73502 | <1% | 81 | $1K | |
| 84703 | <1% | 180 | $1K | |
| 86850 | <1% | 184 | $1K | |
| 73564 | <1% | 71 | $1K | |
| 87040 | <1% | 164 | $1K | |
| 86677 | <1% | 82 | $1K | |
| 85027 | <1% | 510 | $1K | |
| 73110 | <1% | 66 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 235 | $1K |
| 71045 | Radiologic examination, chest; single view | <1% | 214 | $981.32 |
| 82951 | <1% | 74 | $964.06 | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $960.91 |
| 87899 | <1% | 68 | $914.81 | |
| 76937 | <1% | 55 | $869.54 | |
| 93971 | <1% | 17 | $846.19 | |
| 82670 | <1% | 37 | $839.40 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 60 | $810.49 |
| 20610 | <1% | 16 | $796.57 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 24 | $787.02 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 948 | $784.87 |
| 83520 | <1% | 57 | $777.00 | |
| 97597 | <1% | 60 | $737.63 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 307 | $716.04 |
| 72040 | <1% | 47 | $638.80 | |
| 85007 | <1% | 792 | $633.74 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 399 | $628.18 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $623.70 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 402 | $621.95 |
| 83001 | <1% | 30 | $598.85 | |
| 82677 | <1% | 24 | $594.95 | |
| 82248 | <1% | 131 | $581.30 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 57 | $571.60 |
| 80069 | <1% | 131 | $556.20 | |
| 82150 | <1% | 84 | $510.86 | |
| 82105 | <1% | 27 | $468.63 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 327 | $446.65 |
| 84156 | <1% | 164 | $443.56 | |
| 86376 | <1% | 38 | $441.49 | |
| 73080 | <1% | 19 | $436.30 | |
| 99053 | <1% | 771 | $417.11 | |
| 84482 | <1% | 29 | $390.72 | |
| 82952 | <1% | 99 | $384.75 | |
| 86336 | <1% | 24 | $383.48 | |
| 88300 | <1% | 34 | $339.38 | |
| 80050 | General health panel | <1% | 149 | $315.29 |
| 84630 | <1% | 36 | $304.73 | |
| 36591 | <1% | 96 | $258.20 | |
| Q0092 | Set-up portable x-ray equipment | <1% | 197 | $217.07 |
| 84144 | <1% | 14 | $209.60 | |
| R0070 | Transportation of portable x-ray equipment and personnel to home or nursing home, per trip to facility or location, one patient seen | <1% | 197 | $205.48 |
| 82542 | <1% | 12 | $201.96 | |
| 82627 | <1% | 12 | $198.70 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 235 | $189.38 |
| 86901 | <1% | 90 | $180.52 | |
| 83090 | <1% | 13 | $169.54 | |
| 83615 | <1% | 27 | $161.04 | |
| 86664 | <1% | 12 | $153.62 | |
| 82043 | <1% | 30 | $141.97 | |
| J0706 | Injection, caffeine citrate, 5 mg | <1% | 69 | $132.37 |
| 86663 | <1% | 12 | $131.85 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 34 | $127.09 |
| 82784 | <1% | 22 | $123.96 | |
| 84100 | <1% | 44 | $100.76 | |
| 86900 | <1% | 52 | $99.60 | |
| 94760 | <1% | 95 | $96.39 | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 107 | $96.34 |
| 82800 | <1% | 13 | $93.44 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 35 | $78.24 |
| 86430 | <1% | 15 | $76.45 | |
| 87081 | <1% | 13 | $60.80 | |
| 86592 | <1% | 16 | $58.15 | |
| 87205 | <1% | 14 | $42.66 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 49 | $41.41 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 13 | $40.07 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 149 | $28.97 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 12 | $27.25 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 13 | $26.66 |
| 81003 | <1% | 13 | $4.35 | |
| A6235 | Hydrocolloid dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 18 | $0.65 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 22 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 23 | $0.00 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 84 | $-43.27 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 29 | $-661.99 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialERICKSON, JACOB (CEO)
| Provider | Location | Paid |
|---|---|---|
| BMH INC | Blackfoot, ID | $2.60M |
| BMH, INC. | Blackfoot, ID | $2.32M |
| BMH, INC. | Pocatello, ID | $863K |
| BMH, INC. | Idaho Falls, ID | $767K |
| BMH INC | Ammon, ID | $546K |
| BMH, INC | Idaho Falls, ID | $458K |
| BMH, INC | Blackfoot, ID | $323K |
| BMH INC. | Pocatello, ID | $305K |
| BMH INC | Shelley, ID | $299K |
| BMH INC. | Pocatello, ID | $238K |
| BMH INC. | Pocatello, ID | $213K |
| BMH INC. | Idaho Falls, ID | $194K |
| BMH, INC. | Pocatello, ID | $142K |
| BMH INC. | Pocatello, ID | $132K |
| BMH INC. | Pocatello, ID | $54K |
| Mountain River Birthing and Surgery Center LLC | Blackfoot, ID | $6K |
| BMH, INC | Pocatello, ID | $4K |
| BMH, INC. | Idaho Falls, ID | $1K |
| BMH, INC. | Blackfoot, ID | $725.93 |
| BMH INC | Blackfoot, ID | $122.90 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.